MetaCap

Larimar Therapeutics (LRMR) vs MapLight Therapeutics (MPLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Larimar Therapeutics (LRMR) has outperformed MapLight Therapeutics (MPLT) over the past year, losing 11.8% versus a loss of 57.5%. MapLight Therapeutics is the larger company by market cap ($330.1 million vs $328.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LRMR-11.80%MPLT-57.54%
+197%+63%-70%
Nov 21, 20251 yearNov 20, 2026
LRMR-19.28%MPLT-64.89%
+142%+34%-75%
Oct 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LRMR versus MPLT key metrics
MetricLRMRMPLT
Share price$3.14$5.94
Market cap$328.55M$330.12M
1-day change-2.48%-7.48%
YTD return-17.59%-66.18%
1-year return-11.80%-57.54%
5-year return-68.97%—
EPS (TTM)$-1.67$-6.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-165.67M$-161.15M
52-week high$6.42$40.43
52-week low$1.92$5.93
Distance from 52-week high-51.09%-85.31%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.23%+340.24%
Average volume1.38M458.71K
Shares outstanding104.63M52.85M
Employees71133
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LRMR has outperformed MPLT by 45.7 percentage points over the past year.

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

About MapLight Therapeutics

MPLT stock →

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees

LRMR vs MPLT FAQ

Which is bigger, Larimar Therapeutics or MapLight Therapeutics?

MapLight Therapeutics (MPLT) is larger, with a market capitalization of $330.12M compared with $328.55M for Larimar Therapeutics (LRMR).

Which stock has performed better over the past year, LRMR or MPLT?

LRMR returned -11.80% over the past 12 months, compared with -57.54% for MPLT (price return, excluding dividends). Past performance does not predict future results.

Are Larimar Therapeutics and MapLight Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons